A Phase 1/3 Study to Evaluate the Efficacy and Safety of Selinexor, a Selective Inhibitor of Nuclear Export, in Combination with Ruxolitinib, in Treatment-Nave Patients with Myelofibrosis
Multiple Cancer Types
Hematologic,
Phase I
I/III
Mohan, Sanjay
NCT04562389
VICCHEMP2130
